June 25, 2018 / 5:15 AM / 24 days ago

Roche's Tecentriq cocktail boosts survival in small cell lung cancer

ZURICH, June 25 (Reuters) - Swiss drugmaker Roche said on Monday that a cocktail of its immunotherapy Tecentriq with chemotherapy boosted survival of patients with previously untreated extensive-stage small cell lung cancer compared with chemotherapy alone.

"These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer," Roche said in a statement. (Reporting by John Miller; Editing by Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below